Basic research for the development of personalized therapeutic strategies against a rare renal cell carcinoma
| Project/Area Number |
18K07236
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 腎細胞がん / ANGPTL2 / 尿中バイオマーカー / miRNA / がん免疫 / TFE3融合遺伝子 / 転座型腎細胞がん / 稀少腎細胞がん |
|---|
| Outline of Final Research Achievements |
In this study, we challenged to identify urinary biomarkers for early diagnosis of Xp11.2 translocation renal cell carcinoma (tRCC) and examined molecular mechanisms underlying the development and progression of Xp11.2 translocation renal cell carcinoma. Our results showed that miR-204-5p in urinary exosomes could be a useful biomarker for early diagnosis of patients with Xp11.2 tRCC. We also demonstrated that tumor cell-derived ANGPTL2 accelerates the progression of Xp11.2 tRCC, suggesting that ANGPTL2 signaling could be a novel therapeutic target. Moreover, we showed that tumor stroma-derived ANGPTL2 suppresses tumor progression by facilitating the activation of anti-tumor immune responses.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、稀少がんであるが故に治療法や診断マーカーの研究開発が困難なXp11.2転座型腎細胞がんについて、そのモデルマウスを独自に開発し、早期診断に利用可能な新規バイオマーカーや新規治療標的分子を解明するなど、その成果はXp11.2転座型腎細胞がんの個別化治療戦略の確立に寄与するものである。さらに、本研究の成果は、ANGPTL2シグナルを介した抗腫瘍免疫応答制御の解明といった学術的意義も有する。
|
Report
(4 results)
Research Products
(16 results)
-
-
-
-
[Journal Article] Tumor cell-derived angiopoietin-like protein 2 establishes a preference for glycolytic metabolism in lung cancer cells.2020
Author(s)
Osumi H, Horiguchi H, Kadomatsu T, Tashiro K, Morinaga J, Takahashi T, Ikeda K, Ito T, Suzuki M, Endo M, Oike Y
-
Journal Title
Cancer Sci
Volume: -
Issue: 4
Pages: 1241-1253
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity.2019
Author(s)
Horiguchi H, Kadomatsu T, Kurahashi R, Hara C, Miyata K, Baba M, Osumi H, Terada K, Araki K, Takai T, Kamba T, Linehan WM, Moroishi T, Oike Y.
-
Journal Title
Genes Dev
Volume: 33
Issue: 23-24
Pages: 1641-1656
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] MiR-204-5p: a novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.2019
Author(s)
Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y.
-
Journal Title
Cancer Science
Volume: 印刷中
Issue: 6
Pages: 1897-1908
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease.2019
Author(s)
Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM
-
Journal Title
Molecular Cancer Research
Volume: 印刷中
Issue: 8
Pages: 1613-1626
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
